Purpose of the study: to conduct a systemic literature review regarding current diagnosis and treatment strategies for ewing sarcoma (ES). Material and Methods. The search for material for the review was conducted in the Medline, Web of science and Russian science Citation Index libraries. a total of 352 sources published during the period from 2004 to 2024 were selected for the analysis. The review was based on 67 publications. Results. While surgery and radiation therapy have been crucial in treating ES, the introduction of chemotherapy has significantly improved patient outcomes. Many effective multidrug chemotherapy regimens developed in the 1960s and 1970s are still used as induction therapy for ES patients today. Much attention is paid to the problem of treating patients with relapses and refractory disease that are poorly responsive to chemotherapy. Currently, studies are underway to assess the feasibility of combining cytostatics with tyrosine kinase inhibitors, Dna repair inhibitors, inhibitors of other molecules, and autologous vaccines. available data regarding the effectiveness of high-dose chemotherapy with autologous transplantation and CaR-t cell therapy are contradictory. an obstacle to getting relatively rapid results from these studies is the small number of patients, which dictates the need for multi-center patient recruitment. In addition, the increased requirements of state regulatory bodies due to the childhood and adolescence of a large proportion of patients leave their mark. Conclusion. Despite significant advances in the treatment of primary localized ewing sarcoma, the treatment results of metastatic disease and relapses are far from satisfactory. While the possibilities of cytostatic therapy appear to be exhausted, molecular targeting drugs have not yet received convincing evidence of clinical significance. However, future advances in treatment should still be expected from drugs that target the key points of the ES oncogenesis.
Фалалеева et al. (Wed,) studied this question.